The ERA-EDTA Registry Annual Report 2018 : A summary

Funding Information: The ERA-EDTA Registry is funded by the ERA-EDTA. This article was written by A.K. et al. on behalf of the ERA-EDTA Registry, which is an official body of the ERA-EDTA. In addition, V.S.S. reports grants from ERA-EDTA, during the conduct of the study; S.B. reports personal fees from Astra Zeneca, outside the submitted work; P.F. reports personal fees from Baxter, outside the submitted work; and K.J.J. reports grants from ERA-EDTA, during the conduct of the study. Publisher Copyright: © The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.Background. The European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry collects data on kidney replacement therapy (KRT) via national and regional renal registries in Europe and countries bordering the Mediterranean Sea. This article summarizes the 2018 ERA-EDTA Registry Annual Report, and describes the epidemiology of KRT for kidney failure in 34 countries. Methods. Individual patient data on patients undergoing KRT in 2018 were provided by 34 national or regional renal registries and aggregated data by 17 registries. The incidence and prevalence of KRT, the kidney transplantation activity and the survival probabilities of these patients were calculated. Results. In 2018, the ERA-EDTA Registry covered a general population of 636 million people. Overall, the incidence of KRT for kidney failure was 129 per million population (p.m.p.), 62% of patients were men, 51% were 65 years of age and 20% had diabetes mellitus as cause of kidney failure. Treatment modality at the onset of KRT was haemodialysis (HD) for 84%, peritoneal dialysis (PD) for 11% and pre-emptive kidney transplantation for 5% of patients. On 31 December 2018, the prevalence of KRT was 897 p.m.p., with 57% of patients on HD, 5% on PD and 38% living with a kidney transplant. The transplant rate in 2018 was 35 p.m.p.: 68% received a kidney from a deceased donor, 30% from a living donor and for 2% the donor source was unknown. For patients commencing dialysis during 2009-13, the unadjusted 5-year survival probability was 42.6%. For patients receiving a kidney transplant within this period, the unadjusted 5-year survival probability was 86.6% for recipients of deceased donor grafts and 93.9% for recipients of living donor grafts.Peer reviewe

The ERA-EDTA Registry Annual Report 2018: A summary

Background. The European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry collects data on kidney replacement therapy (KRT) via national and regional renal registries in Europe and countries bordering the Mediterranean Sea. This article summarizes the 2018 ERA-EDTA Registry Annual Report, and describes the epidemiology of KRT for kidney failure in 34 countries. Methods. Individual patient data on patients undergoing KRT in 2018 were provided by 34 national or regional renal registries and aggregated data by 17 registries. The incidence and prevalence of KRT, the kidney transplantation activity and the survival probabilities of these patients were calculated. Results. In 2018, the ERA-EDTA Registry covered a general population of 636 million people. Overall, the incidence of KRT for kidney failure was 129 per million population (p.m.p.), 62% of patients were men, 51% were 65 years of age and 20% had diabetes mellitus as cause of kidney failure. Treatment modality at the onset of KRT was haemodialysis (HD) for 84%, peritoneal dialysis (PD) for 11% and pre-emptive kidney transplantation for 5% of patients. On 31 December 2018, the prevalence of KRT was 897 p.m.p., with 57% of patients on HD, 5% on PD and 38% living with a kidney transplant. The transplant rate in 2018 was 35 p.m.p.: 68% received a kidney from a deceased donor, 30% from a living donor and for 2% the donor source was unknown. For patients commencing dialysis during 2009-13, the unadjusted 5-year survival probability was 42.6%. For patients receiving a kidney transplant within this period, the unadjusted 5-year survival probability was 86.6% for recipients of deceased donor grafts and 93.9% for recipients of living donor grafts

”Här hämtar man kraft” : en kvalitativ studie om kvinnors upplevelser av deltagande i Qvinnoqulan, ett projekt för kvinnor på väg ur missbruk

The purpose of this study was to increase the knowledge and understanding of what impact support-groups, such as represented by Qvinnoqulan, can have on women with drug-addiction. The questions at issue for the essay was: How does a selection of women who participate in Qvinnoqulan describe their thoughts, experiences and reflections of the group? What sense has Qvinnoqulan made for the women on a personal level and for contributing to live a life without drugs? To answer the questions a qualitative method was used and five interviews were made with women who participated in the activities of Qvinnoqulan. To analyze the data a social constructionist perspective and an empowerment perspective was used. The result of the study showed that the women were in the process of rebuilding a new life without drugs and reconstructing a new identity. Qvinnoqulan played an important role in that process and was functioning as a safe place in between the two different types of lifestyles; life with drugabuse and life without drugs. Elements such as female friendship, honesty, understanding and sharing familiar experiences with other women were important to maintain a life free from drugs